| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Cardiovascular System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Cardiovascular System | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Cardiovascular System |
Recent Updates
Recently added Catalysts
Inhibikase Therapeutics, Inc.$2.35
+0.06 (+2.58%)
D 35Pipeline Score Overvalued Biotech · Clinical
Market Cap
223.14 M
EPS
-0.43
P/E Ratio
-
Value Trade
1.43 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
10.84 M
Operating CF
-12.06 M
Total Assets
173.33 M
Total Liabilities
5.71 M
Equity
167.62 M
D/E Ratio
12,345
-8.15 %
Week
-0.59 %
1 Month
-2.87 %
3 Month
7.64 %
6 Month
-93.86 %
5 Year
-97.36 %
All Time
Cash Data
Cash Position
170.37 M
Monthly Burn
4.02 M
Runway
39.9 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
513.87 K
52 Week Range
1.33 - 2.26
% held by Insiders
24.61 %
% held by Institutions
88.13 %
Enterprise Value
52.77 M
Total Shares
132.02 M
Short %
18.35 %
Float Shares
103.76 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Inhibikase Therapeutics, Inc.
184Total events
4Upcoming
23Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
▲Orphan Drug DesignationIKT-001FiledDesignation
Subscribe to view catalyst details
TBD
◆Enrollment UpdateIKT-001FiledTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-11-30 | Risvodetinib | Phase 2 data readout | Phase 2 | — | – | – | – |
2024-11-30 | Risvodetinib | Phase 2 data readout | Phase 2 | — | – | – | – |
2024-11-30 | Risvodetinib | Phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
D35
Pipeline Score $56M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.3x
rNPV / MCap Top 50%
Micro Cap (rank 457 of 913)
Percentile RankInhibikase Therapeutics, Inc. faces pipeline headwinds (35/100), with $225M risk-adjusted pipeline value, led by IkT-001Pro in CML (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IkT-001Pro Small molecule | CML | Phase 1 | NCT05623774 | 10% | $190M | COMPLETED | 64 | - | - | Dec 30, 2024 | - | Nov 6, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IKT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IKT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IKT▲ +7.4%on this news
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
Inhibikase Therapeutics announced that the FDA has granted Orphan Drug Designation to IKT-001 for the treatment of Pulmonary Arterial Hypertension (PAH). This designation highlights the significant unmet medical need for the approximately 50,000 PAH patients in the U.S. IKT-001, a prodrug of imatinib mesylate, has shown promising pre-clinical results, including improved pulmonary vascular markers and reduced gastrointestinal toxicity.
Read more →IKT▲ +5.1%on this news
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
Inhibikase Therapeutics has successfully sold 25 million shares for $50 million through its at-the-market facility. This capital will support ongoing operations, particularly the Phase 3 IMPROVE-PAH clinical study for its lead product, IKT-001, aimed at treating Pulmonary Arterial Hypertension. The company anticipates that this funding will ensure operational continuity until key data is available.
Read more →IKTInhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics reported its financial results for Q1 2026, highlighting the enrollment of the first patient in the IMPROVE-PAH study. The company has secured regulatory approvals in 16 countries, facilitating the initiation of clinical sites. Despite a net loss of $16.4 million, Inhibikase maintains a strong cash position of $170.4 million and plans to present at the upcoming American Thoracic Society Conference.
Read more →IKTInhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
Inhibikase Therapeutics has enrolled the first patient in its global Phase 3 study, IMPROVE-PAH, evaluating IKT-001 for Pulmonary Arterial Hypertension (PAH). This pivotal trial aims to assess the drug's efficacy in reducing pulmonary vascular resistance and improving patient outcomes. The study features an adaptive design and aims to enroll approximately 486 patients across 180 sites worldwide.
Read more →IKTInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inhibikase Therapeutics announced the grant of non-qualified stock options to five new non-executive employees under its 2026 Inducement Equity Plan. The options, totaling 685,718 shares, have an exercise price of $1.68 and will vest over a period of four years. This move aims to attract and retain talent as the company advances its clinical programs, including a pivotal Phase 3 study for its lead product candidate, IKT-001, targeting pulmonary arterial hypertension.
Read more →IKTInhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics reported its financial results for 2025, highlighting a transition to a pivotal Phase 3 study for Pulmonary Arterial Hypertension (PAH). The company has initiated regulatory submissions in over 20 countries and has begun enrolling patients in the IMPROVE-PAH study. Despite a significant cash position, the company reported a net loss that increased from the previous year.
Read more →IKTInhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Inhibikase Therapeutics, Inc. has announced the pricing of its public offering, which includes 46,091,739 shares of common stock and pre-funded warrants to purchase an additional 22,873,779 shares. Priced at $1.45 per share, the offering is expected to raise approximately $100 million for the company, with proceeds aimed at advancing its therapeutic portfolio for pulmonary arterial hypertension. The offering is set to close on November 24, 2025, pending customary closing conditions.
Read more →IKTInhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
Inhibikase Therapeutics announced that it will advance IKT-001 to a global pivotal Phase 3 clinical study for Pulmonary Arterial Hypertension (PAH), expected to initiate in Q1 2026. This follows a Type C Meeting response from the FDA, allowing the company to implement an adaptive study design. The new study is projected to reduce the timeline for potential FDA approval by three years. IKT-001, a novel pro-drug of imatinib, aims to improve patient outcomes in treating PAH, addressing previous discontinuation issues.
Read more →IKTCorporate Overview November 2025 Disclaimer This presentation contains information that may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
Inhibikase Therapeutics, Inc. presented forward-looking statements concerning its drug candidate IKT-001 for pulmonary arterial hypertension (PAH). While the company hopes to address a significant unmet need with IKT-001, uncertainties surrounding clinical trial execution and potential high discontinuation rates of similar therapies pose risks. The company's strong leadership and anticipated initiation of a Phase 3 trial in early 2026 highlight a focused approach to tackling PAH.
Read more →IKTInhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Inhibikase Therapeutics has announced a proposed underwritten public offering of its common stock and pre-funded warrants aimed at certain investors. The company is granting underwriters a 30-day option to purchase up to an additional 15% of the total shares offered. This offering is contingent upon market and other conditions, and no guarantees are provided regarding its completion or the terms involved. A prospectus will be filed with the SEC to detail the terms of the offering further.
Read more →IKTInhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics reported its financial results for Q3 2025, highlighting a net loss of $11.9 million and increasing R&D expenses. The company is focusing on advancing IKT-001, a prodrug aimed at treating Pulmonary Arterial Hypertension (PAH), with the intention to begin a Phase 2b clinical trial by the end of 2025. Despite a cash position of $77.3 million, the significant rise in losses and expenses raises concerns about the sustainability of its current strategy.
Read more →IKTInhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
Inhibikase Therapeutics has appointed Timothy Pigot as Chief Commercial and Strategy Officer. Pigot brings over 30 years of experience in the pharmaceutical industry, particularly in the pulmonary arterial hypertension (PAH) market. His insights and connections are expected to aid the company's progress as it advances its lead product candidate, IKT-001, toward late-stage clinical trials.
Read more →IKTInhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics reported its financial results for Q2 2025, highlighting advancements in its clinical program for IKT-001, aimed at treating Pulmonary Arterial Hypertension (PAH). The company plans to initiate a Phase 2b clinical study in the latter half of 2025. Despite a strong cash position, the company reported increased net losses and rising R&D expenses compared to the previous year.
Read more →IKTInhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension
Inhibikase Therapeutics has announced its financial results for the first quarter of 2025, reporting a net loss of $13.7 million as it prepares to advance its treatment IKT-001 into a Phase 2b clinical trial for pulmonary arterial hypertension (PAH) in the second half of the year. The company reported an increase in R&D expenses, largely due to costs associated with its recent acquisition of CorHepta. Despite these challenges, IKT maintains a strong cash position with $93.2 million available to fund its activities moving forward.
Read more →IKTInhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
Inhibikase Therapeutics has appointed David McIntyre as Chief Financial Officer, effective April 14, 2025. McIntyre brings over two decades of experience in the life sciences sector, having held various executive roles and expertise in financial strategy. The company aims to leverage his skills to advance its lead product, IkT-001, for pulmonary arterial hypertension.
Read more →IKT▲ +11.3%on this newsshared move
CONSULTING AGREEMENT This Agreement is made and entered into as of
Inhibikase Therapeutics, Inc. has entered into a consulting agreement with Garth Lees-Rolfe as of April 11, 2025. The terms include a four-month engagement, during which Lees-Rolfe will provide specified consulting services. The agreement outlines compensation details, establishes Lees-Rolfe's status as an independent contractor, and emphasizes confidentiality and intellectual property rights. Furthermore, it provides for termination conditions and remedies in case of breach.
Read more →IKTInhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension
Inhibikase Therapeutics has announced its financial results for 2024, highlighting a strategic focus on advancing IkT-001 into a Phase 2b trial in pulmonary arterial hypertension (PAH). The company experienced an increase in net loss to $27.5 million, as opposed to $19.1 million in 2023. To support its growth, Inhibikase appointed Chris Cabell and John Adams, experienced leaders in the PAH area, to its management team. The company features a strong cash position of $97.5 million, which will help facilitate its clinical development plans.
Read more →IKT▼ -16.5%on this news
Inhibikase Announces Expansion of Senior Leadership Team
Inhibikase Therapeutics has expanded its senior leadership team by appointing Chris Cabell as President and Head of Research & Development, and John Adams as Chief Scientific Officer. Both leaders bring extensive experience in pulmonary arterial hypertension (PAH) and are expected to enhance the company's efforts in developing IkT-001. Additionally, Vince Aurentz joins the Board of Directors, contributing further strategic expertise.
Read more →IKT▲ +10.6%on this news· ran to +31% by day 1
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
Inhibikase Therapeutics has appointed Mark Iwicki as CEO, effective February 14, 2025, succeeding founder Dr. Milton H. Werner. Amit Munshi has been appointed as the independent Chair of the Board. The new leadership aims to advance IkT-001Pro, a treatment for pulmonary arterial hypertension (PAH), through clinical development, leveraging recent financing.
Read more →IKTInhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
Inhibikase Therapeutics reported its third quarter financial results for 2024, revealing a net loss of $5.8 million. The company highlighted a recent financing round worth up to $275 million, intended to support the advancement of its pipeline candidate IkT-001Pro into late-stage clinical trials for pulmonary arterial hypertension. The firm also announced the addition of new members to its Board of Directors to enhance leadership. The upcoming reporting of data from its 201 trial is anticipated in Q4 2024.
Read more →IKTInhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension IkT-001Pro to be developed as a New Molecular En
Inhibikase Therapeutics has successfully closed a financing round of up to $275 million to advance its lead candidate, IkT-001Pro, into a late-stage clinical trial for pulmonary arterial hypertension (PAH). This novel treatment is designed to be the first oral disease-modifying therapy for PAH, primarily affecting women aged 30 to 60. The funding will support the Phase 2b trial and enhance the company’s strategic capabilities with the addition of experienced biopharmaceutical leaders to its Board of Directors. IkT-001Pro aims to improve upon the safety and tolerability issues associated with its predecessor, imatinib, thereby potentially benefiting millions of patients.
Read more →IKT▲ +5.9%on this news· ran to +34% by day 3
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension Aggregate investment of up t
Inhibikase Therapeutics announced a $110 million private placement aimed at advancing IkT-001Pro into a Phase 2b trial for pulmonary arterial hypertension. Healthcare-focused investors led by Soleus Capital contributed to this financing, which is part of a larger potential investment totaling approximately $275 million. This influx of capital is intended to facilitate trial initiation and general corporate purposes. Additionally, the announcement included changes to the board of directors, enhancing the company's leadership team.
Read more →IKT▲ +5.9%on this news· ran to +34% by day 3
PAH | BUSINESS PRESENTATION Clinical Development of Disease-Modifying Therapeutics for Pulmonary Arterial Hypertension Inhibikase.com : IKT DISCLAIMER This presentation contains information that may constitute "forward-l
Inhibikase Therapeutics is advancing its clinical program for IkT-001Pro, a prodrug of imatinib mesylate, intended for the treatment of Pulmonary Arterial Hypertension (PAH). The company recently filed an IND and received a positive 'Study May Proceed' letter from the FDA. With a sizable global market for PAH therapies and a strong patent portfolio, Inhibikase aims to address the high unmet needs in this therapeutic area. However, they face challenges due to past adverse events associated with imatinib that hindered its approval.
Read more →IKT▼ -5.8%on this news
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
Inhibikase Therapeutics reported its financial results for the second quarter of 2024 and highlighted key developments in its clinical pipeline. The company completed enrollment for the Phase 2 trial of risvodetinib in untreated Parkinson's disease and plans to release topline data by November 2024. Additionally, IkT-001Pro is advancing as a potential treatment for Pulmonary Arterial Hypertension, with IND filing submitted to the FDA. Financially, the company showed a net loss of $5.0 million but raised $4 million to progress its clinical trials.
Read more →IKTInhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) will report its second quarter financial results for 2024 on August 14, 2024. Following the announcement, a conference call and webcast will be held on August 15 for a corporate update and financial review. The company focuses on developing therapeutics for Parkinson's disease and related conditions, including its lead program, risvodetinib. Inhibikase is committed to enhancing the patient experience with innovative drug delivery technologies.
Read more →IKT▲ +12.8%on this news
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease
Inhibikase Therapeutics announced the completion of enrollment for its Phase 2 '201' trial assessing risvodetinib, a selective c-Abl inhibitor for untreated Parkinson's disease. The trial aims to evaluate the safety and efficacy of the drug across 120 participants at multiple U.S. study sites. With results expected in the fourth quarter of 2024, Inhibikase is poised for discussions with the FDA regarding pivotal Phase 3 trials. The study has produced some adverse events and participant withdrawals, but overall achievement marks a key progress for the company.
Read more →IKTInhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
Inhibikase Therapeutics has announced significant developments in its research programs, including the expansion of its therapeutic pipeline to involve cardiopulmonary diseases. The company reports that the 201 Trial in untreated Parkinson's disease is nearing completion, with 94% enrollment. Additionally, Inhibikase plans to submit an IND application for IkT-001Pro in treating Pulmonary Arterial Hypertension. Nevertheless, the company has also made the strategic decision to discontinue its antiviral development for Progressive Multifocal Leukoencephalopathy.
Read more →IKT▲ +7.5%on this news
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million BOSTON and ATLANTA
Inhibikase Therapeutics has announced a registered direct offering and warrant inducement with a single institutional investor. The offering, which is priced at-the-market, is expected to generate approximate gross proceeds of $4.0 million, facilitating further development of their Parkinson's disease therapeutics. The offering includes common stock and Series A and B warrants, with additional incentives for the investor to exercise certain outstanding warrants. The completion of the offering is anticipated to close shortly, subject to customary closing conditions.
Read more →IKT▼ -11.6%on this newsshared move
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
Inhibikase Therapeutics (IKT) reported its first quarter financial results, revealing a net loss of $4.6 million and a stable cash position of $9.7 million, expected to fund operations until November 2024. The company emphasized clinical progress, with 83% enrollment in the Phase 2 trial for Risvodetinib and positive regulatory interactions for IkT-001Pro aimed at various cancers. Upcoming milestones include topline data from the Risvodetinib trial in the second half of the year, as well as further engagement with the FDA for IkT-001Pro in different indications. Despite a slight increase in net loss, the company's optimistic outlook reflects its commitment to developing innovative therapies for Parkinson's disease and related conditions.
Read more →IKT▲ +29.2%on this newsshared move
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
Inhibikase Therapeutics has announced a request for withdrawal of its S-1 Registration Statement with the SEC. Originally filed on April 19, 2024, this registration has not been approved, and no securities related to it have been sold. This move may reflect challenges faced by the company in securing financing, important for advancing its therapeutic developments for Parkinson's disease and related disorders.
Read more →IKTInhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
Inhibikase Therapeutics announced positive outcomes from its pre-IND meeting with the FDA regarding IkT-001Pro for treating Pulmonary Arterial Hypertension (PAH). The FDA recognized IkT-001Pro as a New Molecular Entity, which may facilitate patent and exclusivity protections. Inhibikase plans to submit an IND application while completing additional studies requested by the FDA. The company is also seeking strategic partnerships to further advance the development of this promising treatment for a disease with high unmet needs.
Read more →IKT▼ -7%on this news· ran to -22% by day 3
Q24 | BUSINESS PRESENTATION Clinical Development of Disease-Modifying Therapeutics for Neurodegenerative Disease, Cancer and Cardiopulmonary Disease Inhibikase.com : IKT DISCLAIMER This presentation shall not constitute
Inhibikase Therapeutics (IKT) has presented its clinical development strategy for disease-modifying therapeutics targeting neurodegenerative diseases, cancer, and cardiopulmonary diseases. The company aims to consolidate up to $13 million in gross proceeds to extend its Phase 2 trial of Risvodetinib for Parkinson's disease. Currently, 77% of participants are enrolled in this ongoing study. The company also reports a promising patent portfolio and plans to approach additional therapies alongside their current pipeline.
Read more →IKTInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs BOSTON and ATLANTA
Inhibikase Therapeutics has provided an update on its development programs, highlighting that the enrollment for its 201 Trial is 75% complete, with expectations to finish by mid-June 2024. The company has been engaging positively with the FDA regarding IkT-001Pro and plans to initiate a 12-month extension study. Additionally, Inhibikase is exploring new indications for IkT-001Pro, including potential applications in cardiopulmonary diseases and Multiple System Atrophy. Despite these advancements, the company highlighted the need for further financial resources to support these initiatives.
Read more →IKTInhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Inhibikase Therapeutics has announced a Pre-IND meeting with the FDA on April 5, 2024, to discuss IkT-001Pro as a treatment for Pulmonary Arterial Hypertension (PAH). The company aims to explore the potential of IkT-001Pro as a safer alternative to imatinib, which had an unsuitable side effect profile for this patient population. The meeting will focus on the proposed late-stage trial design and seek feedback on regulatory pathways for the drug. Pending this meeting's results, the company will consider filing an IND for IkT-001Pro.
Read more →IKTINHIBIKASE THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this Agreement ) is made and entered into effective as of April 1 , 2024 (the Effective Date ), by and between INHIBIKASE THERAPEUTICS, INC. (
Inhibikase Therapeutics, Inc. has entered into an employment agreement with Garth Lees-Rolfe, appointing him as the Chief Financial Officer effective April 1, 2024. The agreement outlines the employment terms, including a base salary of $345,000 per annum, eligibility for an annual target bonus equal to 30% of the base salary, and various employee benefits. Additionally, Lees-Rolfe will receive stock options as part of his compensation package, with terms specifying that one-third will vest over three years.
Read more →IKTInhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Inhibikase Therapeutics announced its financial results for Q4 and full year 2023, showcasing significant clinical progress. The company has successfully completed a pre-NDA meeting with the FDA for its therapy IkT-001Pro and continues to actively enroll patients in its Phase 2 study of Risvodetinib for Parkinson's disease. Despite reporting an increase in net loss and some adverse events in clinical trials, the overall outlook remains optimistic as Inhibikase aims to advance its therapeutic pipeline and bring new treatments to market.
Read more →IKTInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Inhibikase Therapeutics announced that Dr. Milton Werner will present an update on the 201 Trial of risvodetinib at the 2024 AD/PD Meeting in Lisbon. The trial, evaluating risvodetinib in untreated Parkinson's disease patients, has shown positive participant experiences, with interest in continuing into a follow-up study. Although some minor side effects have been reported, none were clinically significant. The trial will continue, with top-line results expected in the latter half of 2024.
Read more →IKTInhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
Inhibikase Therapeutics has announced results from its pre-New Drug Application (NDA) meeting with the FDA regarding IkT-001Pro, a prodrug of imatinib mesylate for treating blood and stomach cancers. The FDA's guidance suggests that a formal risk analysis of medication errors may not be needed, but the company must justify its proposed dosage forms. Additionally, Inhibikase can pursue multiple approved indications previously established for imatinib mesylate. The company is also scheduled for further discussions with the FDA regarding cardiopulmonary applications of IkT-001Pro.
Read more →IKT▼ -8.7%on this news
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers - The Company continues to progress the 201 Tria
Inhibikase Therapeutics has announced the preliminary outcomes of its pre-New Drug Application (NDA) meeting with the FDA for IkT-001Pro, a prodrug aimed at treating blood cancers. The FDA acknowledged a 505(b)(2) pathway as appropriate for approval and provided specific guidance on necessary manufacturing requirements. Despite the positive feedback, the company may need to conduct additional clinical studies and assess bioequivalence. Inhibikase is also progressing with its 201 Trial evaluating risvodetinib in untreated Parkinson's disease, indicating overall growth in its therapeutic pipeline.
Read more →IKT▲ +8.4%on this news
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
Inhibikase Therapeutics announced the publication of Phase 1 clinical study results for risvodetinib, an investigational drug aimed at treating Parkinson's disease. The study showed that the drug was well tolerated by both healthy volunteers and patients with Parkinson's with no serious adverse events reported. Importantly, risvodetinib was able to cross the blood-brain barrier, suggesting its potential efficacy in the central nervous system. Inhibikase is currently advancing its Phase 2 trial and actively enrolling participants.
Read more →IKT▲ +10.7%on this news
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli - Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-President of Finance, to be promoted to Chief Financi
Inhibikase Therapeutics announced the planned retirement of CFO Joseph Frattaroli at the end of Q1 2024. He will be succeeded by Garth Lees-Rolfe, the current VP of Finance, as part of a planned transition. Under Frattaroli's leadership since 2018, the company transitioned into a public entity and secured funding for its research and development programs focused on therapeutics for Parkinson’s disease and related disorders. The promotion of Lees-Rolfe is seen as a positive step for the company's continued growth and strategic direction.
Read more →IKTInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Inhibikase Therapeutics has reported strong progress in its development programs, highlighting a 68% increase in stock price since October. The company has successfully begun patient enrollment for its risvodetinib trials, aiming to address Parkinson's disease and related disorders. Additionally, it plans to submit regulatory documents to the EU in 2024 and has completed evaluations for its cancer drug IkT-001Pro. The company emphasizes a transformative vision for 2024 amid navigating potential financial and clinical challenges.
Read more →IKTInhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro
Inhibikase Therapeutics has received a pre-NDA meeting approval from the FDA to discuss the potential marketing application for IkT-001Pro, targeting up to eight cancer indications. The meeting is scheduled for January 2024, focusing on the requirements for submission and review of bioequivalence data to imatinib mesylate. Recent studies indicated that IkT-001Pro's dosing showed minimal adverse reactions, suggesting a safer alternative to existing therapies for blood and stomach cancers.
Read more →IKTInhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity
Inhibikase Therapeutics recently reported its financial results for Q3 2023, highlighting significant progress in its clinical development programs. The company's lead candidate, risvodetinib, showed promising early results in the Phase 2 '201' trial aimed at treating untreated Parkinson's disease, with 24 participants enrolled so far. Additionally, Inhibikase received Orphan Drug Designation for risvodetinib in Multiple System Atrophy, reflecting the urgent need for treatment options in this area. The company also reported a net loss of $4.60 million for the quarter, slightly higher than the previous year, while their cash position remains stable with $16.83 million available to support ongoing operations.
Read more →IKTInhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023
Inhibikase Therapeutics, a clinical-stage pharmaceutical company focused on Parkinson's disease, has announced it will release its financial results for the third quarter on November 14, 2023. Following this announcement, the company will host a conference call for investors on November 15, 2023, to discuss the results and provide a corporate update. The firm has a multi-therapeutic pipeline, concentrating on neurodegeneration and innovative drug delivery technologies.
Read more →IKT▲ +5.9%on this news
Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment
Inhibikase Therapeutics has shared promising results from the 201 Trial evaluating risvodetinib in untreated Parkinson's disease, highlighting improvements in motor and non-motor functions among participants. The trial analysis presented at a congress showed positive changes for those on the 200 mg dose, while no significant adverse effects were reported. The company is actively working on participant enrollment, with significant interest noted, as 171 individuals have been pre-qualified through its patient portal. However, the small participant group limits definitive conclusions about clinical benefits from the findings.
Read more →IKT▼ -26.4%on this news· ran to -42% by day 3
Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy
Inhibikase Therapeutics has announced that its drug risvodetinib has been granted Orphan Drug Designation by the FDA for treating Multiple System Atrophy (MSA). This designation emphasizes the significant unmet medical need, as there are currently no approved therapies for MSA. The company plans to move forward with clinical studies following promising preclinical data. Risvodetinib aims to potentially modify disease progression in this aggressive form of Parkinsonism.
Read more →IKT▲ +17.8%on this news
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity BOSTON and ATLANTA
Inhibikase Therapeutics has issued a letter to shareholders addressing recent volatility in its stock price. The company emphasizes its ongoing progress in developing therapies for Parkinson's disease and related disorders, particularly highlighting the safety data from risvodetinib presented at the Movement Disorder Society Congress. Despite positive updates on clinical trials and financial stability, the company acknowledges the recent sharp decline in its stock value as a concern for shareholders. Inhibikase remains committed to increasing shareholder value and reconciling this disconnect.
Read more →IKTBy electronic delivery to: mhwerner@inhibikase.com; jfrattaroli@inhibikase.com
Inhibikase Therapeutics has successfully regained compliance with Nasdaq Listing Rule 5550(a)(2) after its common stock fell below the required minimum bid price of $1.00. The company met the necessary conditions by maintaining a closing bid price of $1.00 per share or greater for the past 10 consecutive business days. This development signals a positive turnaround for the company in terms of stock market compliance.
Read more →IKTInhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split BOSTON and ATLANTA
Inhibikase Therapeutics has announced a 1-for-6 reverse stock split effective June 30, 2023, in order to comply with Nasdaq's minimum bid price requirements. This split was approved by stockholders on June 23, 2023, and will adjust the total number of shares outstanding from approximately 31.6 million to about 5.3 million. Stockholders will see their shares converted automatically without any change in their par value, maintaining the overall equity percentage. The company continues its focus on developing therapeutics for Parkinson's and related disorders amidst this strategic move.
Read more →IKT▼ -5.5%on this news· ran to -23% by day 3
Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced At a Premium to Market Under Nasdaq Rules BOSTON and ATLANTA
Inhibikase Therapeutics announced a $10 million capital raise through a concurrent registered direct offering and private placement of shares. The company will issue over 11 million shares at a price above market value, a move seen as a positive sign of investor confidence. The expected use of proceeds includes supporting clinical trials and development activities. The closing of the offerings is planned for January 27, 2023, pending satisfaction of customary closing conditions.
Read more →IKT▼ -5.5%on this news· ran to -23% by day 3
Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson s Disease - Phase 2a 201 clinical trial will resume immediately at 50 and 100 mg doses- -Additional safety and pharmacoki
Inhibikase Therapeutics has announced that the FDA has lifted the full clinical hold on its drug IkT-148009 for Parkinson's disease. The Phase 2a 201 clinical trial will resume immediately, testing the drug at 50 mg and 100 mg doses while also implementing additional safety and pharmacokinetic measurements. The company emphasizes that it is working to restart clinical trial sites and enroll patients in a timely manner. The FDA's decision was influenced by Inhibikase's thorough responses regarding safety and trial protocol modifications.
Read more →IKT▲ +14.3%on this news· ran to +33% by day 3
Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity Company to host conference call and webcast on
Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Company to host conference call and webcast on November 15, 2022 at 8:00am ET BOSTON and ATLANTA, November 14, 2022 Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ( Inhibikase or Com
Read more →IKT▼ -40.9%on this news
Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs BOSTON and ATLANTA, November 7 Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ( Inhibikase or Company ), a clinical-stage pharmaceutical company dev
Inhibikase Therapeutics Announces FDA Clinical Hold on IkT-148009 Programs BOSTON and ATLANTA, November 7 Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ( Inhibikase or Company ), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify t
Read more →IKT▼ -8.1%on this news· ran to -19% by day 3
IkT-148009 As A Potential Disease-Modifying Therapy in Parkinson s Disease Poster 789 Werner MH,1,7 Karuppagounder SS,2,3 Rush R,1 Kelly T,1 Dawson TM,2-3,5,7 Dawson VL2-4,6,7 1Inhibikase Therapeutics, Inc., Atlanta, GA,
IkT-148009 As A Potential Disease-Modifying Therapy in Parkinson s Disease Poster 789 Werner MH,1,7 Karuppagounder SS,2,3 Rush R,1 Kelly T,1 Dawson TM,2-3,5,7 Dawson VL2-4,6,7 1Inhibikase Therapeutics, Inc., Atlanta, GA, 30339, USA; 2Neuroregeneration and Stem Cell Programs, Ins
Read more →IKTInhibikase Therapeutics Appoints Gisele Dion to Board of Directors BOSTON and ATLANTA
Inhibikase Therapeutics Appoints Gisele Dion to Board of Directors BOSTON and ATLANTA, September 1, 2022 Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson s disease and rel
Read more →IKT▼ -13.6%on this news
Q 2022 | BUSINESS PRESENTATION Clinical Development of Disease-Modifying Therapeutics for Neurodegenerative Disease & Cancer Inhibikase.com : IKT DISCLAIMER This presentation shall not constitute an offer to sell or a so
Disease-Modifying Therapeutics for Neurodegenerative Disease & Cancer Inhibikase.com : IKT DISCLAIMER This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or juri
Read more →IKTThis presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation,
Clinical Development of Disease- Modifying Therapeutics for Parkinson's and Related Disorders 2Q 2022 BUSINESS PRESENTATION IKT Exhibit 99.1 This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale
Read more →IKTIKT Parkinson's Disease Modification Through Abl-kinase Inhibition AD-PD 2022, March 18 2022 Disclosures Dr. Milton Werner is the Founder, Chief Executive and largest shareholder of Inhibikase Therapeutics, Inc. 2 2 Disc
Abl-kinase Inhibition AD-PD 2022, March 18 2022 Disclosures Dr. Milton Werner is the Founder, Chief Executive and largest shareholder of Inhibikase Therapeutics, Inc. 2 2 Disclaimer This presentation shall not constitute an offer to sell or a solicitation of an offer to buy a
Read more →IKT▼ -7.1%on this news
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson's and Related Disorders 1Q 2022 BUSINESS PRESENTATION IKT 2 This presentation shall not constitute an offer to sell or a solicitation
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson's and Related Disorders 1Q 2022 BUSINESS PRESENTATION IKT 2 This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any
Read more →IKT▲ +9.7%on this news
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson's and Related Disorders 4Q 2021 BUSINESS PRESENTATION IKT 2 2 This presentation shall not constitute an offer to sell or a solicitati
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson's and Related Disorders 4Q 2021 BUSINESS PRESENTATION IKT 2 2 This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be an
Read more →IKT▲ +6.1%on this news
IKT Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson's and Related Disorders 3Q 2021 BUSINESSPRESENTATION Disclaimer This presentation shall not constitute an offer to sell or a soli
the Functional Loss in Parkinson's and Related Disorders 3Q 2021 BUSINESSPRESENTATIONExhibit 99.1 IKT Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson's and Related Disorders 3Q 2021 BUSINESSPRESENTATION Disclaimer This presentation shall n
Read more →IKTInhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock ATLANTA
Inhibikase Therapeutics Announces Closing of Follow-On Offering ATLANTA, June 18, 2021 /PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson s disease and related
Read more →IKTInhibikase Therapeutics Prices Follow-On Public Offering of Common Stock ATLANTA
Inhibikase Therapeutics Prices Follow-On Public Offering of ATLANTA, June 15, 2021 /PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson s disease and related diso
Read more →IKTIKT Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson's and Related Disorders 2Q 2021 BUSINESS PRESENTATION Disclaimer This presentation shall not constitute an offer to sell or a sol
the Functional Loss in Parkinson's and Related Disorders 2Q 2021 BUSINESS PRESENTATIONExhibit 99.1 IKT Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson's and Related Disorders 2Q 2021 BUSINESS Disclaimer This presentation shall not constitut
Read more →IKTInhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity ATLANTA
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent ATLANTA, April 1, 2021 Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson s dise
Read more →IKTTherapies in Clinical Development to Reverse the Progression of Neurodegeneration in Parkinson's Disease 1Q 2021 I NVESTOR PRESENTATION IKT 2 2 This presentation shall not constitute an offer to sell or a solicitation of
Therapies in Clinical Development to Reverse the Progression of Neurodegeneration in Parkinson's Disease 1Q 2021 I NVESTOR PRESENTATION IKT 2 2 This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sal
Read more →IKTInhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering ATLANTA
Therapeutics, Inc. Announces Pricing of its Initial Public Offering ATLANTA, December 22, 2020- Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders that arise inside and outsi
Read more →IKTInhibikase Therapeutics Announces Appointment of Elizabeth O’Farrell to its Board of Directors
ATLANTA and BOSTON, April 09, 2019 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc., a pharmaceutical company developing protein kinase inhibitors for the treatment of neurological infections and neurodegenerative diseases, today announced the appointment of Elizabeth G. O’Farre
Read more →IKTInhibikase Therapeutics Expands its Scientific Advisory Board with the Appointment of Leading Experts in Parkinson’s Disease
ATLANTA and BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc., a pharmaceutical company developing protein kinase inhibitors for the treatment of neurological infections and neurodegenerative diseases, today announced the expansion of its Scientific Advisor
Read more →IKTInhibikase Therapeutics Appoints Leading Experts in Parkinson’s Disease to its Scientific Advisory Board
ATLANTA and BOSTON, March 05, 2019 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc., a pharmaceutical company developing protein kinase inhibitors for the treatment of neurological infections and neurodegenerative diseases, today announced the appointment of three leading scient
Read more →IKTInhibikase Therapeutics Files Two Investigational New Drug Applications for IkT-148009, a Disease-Modifying Therapy for Parkinson’s Disease
ATLANTA and BOSTON, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc., a pharmaceutical company developing protein kinase inhibitors for treatment of neurological infections and neurodegenerative diseases, today announced that it has filed two Investigational New Dr
Read more →Competitive Position
How IKT ranks across every disease it competes inCompetitive Position is a premium feature
See how IKT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial